Due to the urgent need of the hour as only four million people having been fully or partially vaccinated across the country, the University of Health Sciences (UHS) has started working on protocols to start trials for nasal Covid-19 vaccine.
According to the officials, it will be a single dose vaccine, which does not require a syringe. The clinical trial is expected to commence in six to eight weeks after approval from three committees is obtained.
On the other hand, the country reported 3,060 new cases and 57 deaths in a single day.
While talking to Dawn, UHS Vice Chancellor Dr Javed Akram stated the university had started developing protocols for the clinical trial of the nasal vaccine.
“The vaccine will be single dose and has been manufactured by the Cansino Biologics whose single dose injectable vaccine is already being used in Pakistan. Nasal vaccines are usually given to children but there will be no age limit for it and it can be administered to both children and adults,” he said.
